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In the present study, increased levels of ANKHD1 mRNA and protein expression in leukemia cell lines are reported, as compared with normal
hematopoietic cells. Furthermore, a higher expression of ANKHD1 mRNA was detected in primary acute leukemia samples than in normal
hematopoietic cells (P=0.002). ANKHD1 was detected in the cytosolic and membrane fraction of cells and was co-immunoprecipitated with
SHP2 in protein extracts of K562 and LNCaP cell lines. These findings suggest a role for ANKHD1 as a scaffolding protein that may be
associated with the abnormal phenotype of leukemia cells.
© 2006 Elsevier B.V. All rights reserved.Keywords: ANKHD1; MASK; Ankyrin repeat; SHP2 phosphatase; Acute leukemia1. Introduction
Ankyrin-repeat-containing proteins regulate multiple cellu-
lar functions including transcriptional and cell-cycle regulation,
ion channel, cell survival and cell signaling and participate in
protein–protein interactions via their repeat motifs [1–4].
Multiple ankyrin repeat and single KH domain protein,
MASK, was first identified in Drosophila melanogaster
through a genetic screen designed to identify proteins that
interact with the protein–tyrosine phosphatase Corskscrew
(CSW), homolog to SH2-containing protein–tyrosine phospha-
tase (SHP2) in humans [5]. The phenotypic characterization of
MASK in Drosophila suggests that it is a novel protein
involved in receptor tyrosine kinase signaling (RTKs) and its
activity is required for cell differentiation, cell survival and cell
proliferation in Drosophila eyes [5]. In humans, an orthologous
protein of Drosophila MASK, ANKHD1 (Ankyrin Repeat and⁎ Corresponding author. Rua Carlos Chagas, 480, Cidade Universitária
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doi:10.1016/j.bbadis.2006.07.010KH Domain Containing 1), previously named hMASK, was
first identified in LNCaP, a prostate cancer cell line, and
described by Poulin et. al. [6]. However, protein expression
patterns or protein interactions of ANKHD1 have not yet been
described.
The nonreceptor protein–tyrosine phosphatase SHP2,
encoded by the PTPN11 gene, is a signal-enhancing
component of growth factor, cytokine and extracellular
matrix receptor signaling and plays an important role in
regulating cell proliferation, differentiation and migration
[7,8]. Recent studies implicate SHP2 in human disease,
including Noonan syndrome [9], sporadic juvenile myelo-
monocytic leukemia, childhood myelodysplastic syndrome,
B-cell precursor acute lymphoblastic leukemia (ALL),
pediatric and adult acute myeloid leukemia (AML) [10–13]
and some solid tumors [14]. More recently, SHP2 has been
shown to be overexpressed in primary leukemia cells and in
leukemia cell lines, and suppression of SHP2 expression
induces apoptosis and growth inhibition in leukemia clono-
genic cells [15].
Since MASK was first isolated through a genetic screen
designed to identify proteins that interact with CSW/SHP2,
the characterization of ANKHD1 expression in humans and
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study was aimed to evaluate the expression of ANKHD1
mRNA and protein in normal tissues, normal hematopoietic
cells, leukemia cell lines and primary acute leukemia samples.
In addition, the association of ANKHD1 with SHP2 was
studied in leukemia cell lines and the prostate cancer cell line,
LNCaP.
2. Materials and Methods
2.1. Primary leukemia samples
A total of 38 adult cases (patient age range 18–83 years, median 47 years)
diagnosed with acute leukemia at the Hematology and Hemotherapy Center of
the State University of Campinas were studied, including 7 ALL, 1 biphenotypic
acute leukemia and 30 AML (1 M0, 5 M1, 6 M2, 3 M3, 10 M4, 3 M5, 1 M6,
1 M7) based on the French-American-British (FAB) classification. Primary
leukemia cell samples from bone marrow aspirate were obtained from patients
before any treatment. The National Ethical Committee Board approved the study
and informed-written consent was obtained from all patients. Normal
hematopoietic cells (n=11), including bone marrows (n=7) and peripheral
blood mononuclear cells (PBMNC) (n=4), were obtained from healthy donors.
After removing erythrocytes by hemolysis, remaining cells were submitted to
protein or RNA extraction.
2.2. Human leukemia cell lines
A panel of human leukemia cell lines was used which included KG-1, HEL,
K562, NB4, HL-60, Jurkat, MOLT4, Raji, Daudi and Namalwa. A prostate
cancer cell line, LNCaP, was used as a positive control. All cell lines were
obtained from ATCC, Philadelphia, PA. Cells were cultured in RPMI containing
10% fetal calf serum and glutamine with addition of penicillin/streptomycin and
amphotericin B and were maintained at 37 °C, 5% CO2. For experiments, cells
were seeded at a density of 3×105 cells/ml, cultured around 7 days and collected
at an exponential phase of growth.
2.3. Protein analysis by immunoblotting
Equal amounts of protein were used for total extracts or for
immunoprecipitation with specific antibodies followed by SDS-PAGE and
Western blot analysis with the indicated antibodies and ECL Western Blotting
Analysis System (Amersham Pharmacia Biotech, UK) as described [16].
Antibody anti-ANKHD1 was raised in a rabbit against a synthetic peptideFig. 1. Increased ANKHD1 mRNA expression in leukemia cell lines. Real-time quan
lines and the LNCaP cell line. Increased levels of ANKHD1 mRNA were detected
cells.(CHPMHQQLSDPSTFSQ) comprising amino acids 2423-2437 from
ANKHD1 exon 32, and was manufactured by Sigma-Aldrich (MO, USA).
Dr. Francis Poullin (Department of Genome Sciences, Lawrence Berkeley
National Laboratory, Berkeley, CA) kindly provided an additional antibody
against ANKHD1 (RC2335) [6]. Monoclonal antibody against phosphotyr-
osine (SC-508) and polyclonal antibodies anti-SHP2 (sc-280), anti-actin
(sc1616), anti-histone deacetylase (sc11419) and horseradish peroxidase-
conjugated secondary antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Rabbit polyclonal normal IgG (sc-2027) (Santa Cruz, CA,
USA) was used as a control for immunoprecipitation.
2.4. Laser confocal analysis
Cells were washed with PBS and fixed with paraformaldehyde containing
4% sucrose. The primary antibody used was anti-ANKHD1. After washing,
the slides were labeled with Alexa Fluor 488-conjugated goat anti-rabbit
antibody (Molecular Probes, Leiden, The Netherlands) for 2 h. Following this
procedure, K562 and Jurkat cells were incubated with TRITC-conjugated
phalloidin (Sigma-Aldrich, MO, USA) at room temperature and coverslips
with ProLong Gold antifade reagent with DAPI (Molecular Probes, Leiden,
The Netherlands) were applied; PBMNC were washed with 2× SSC (0.3 M
NaCl, 0.03 M sodium citrate, pH 7.0), incubated with 100 μg/mL DNase–
RNase in 2× SSC for 20 min at 37 °C, washed with 2× SSC and incubated
with Propidium Iodide (PI) (Molecular Probes), which binds to DNA, for
5 min at room temperature. Coverslips were applied with Vectashield (Vector
Labs, CA, USA). Positive immunoreactivity was visualized by laser confocal
scanning (Zeiss LM510). In the absence of primary antibodies, application of
secondary antibodies (negative controls) failed to produce any significant
staining.
2.5. Subcellular fractionation
Jurkat cells were washed twice and the pellet was resuspended in hypotonic
buffer containing 10 mM HEPES (pH 7.9), 1.4 mMMgCl2 and 10 mM KCl and
allowed to swell on ice for 10 min. Cells were then lysed on ice by vigorous
homogenization by 10 passages of the cell suspension through a 26.5-gauge
needle. The extracts were centrifuged at 500×g for 10 min at 4 °C. The
supernatant was used as a cytosolic and membrane fraction. The pellet was
washed twice with a hypotonic buffer containing 20 mM HEPES (pH 7.9), 25%
Glycerol, 1.5 mM MgCl2, 20 mM KCl and 0.2 mM EDTA and resuspended in
hypertonic buffer containing 20 mM HEPES (pH 7.9), 25% Glycerol, 1.5 mM
MgCl2, 1 M KCl and 0.2 mM EDTA. The homogenate was incubated on ice for
30 min at 4 °C and centrifuged at 14.000×g for 15 min at 4 °C. Supernatant was
used as the nuclear fraction. Equal amounts of proteins were used for Western
blot analysis.titative RT-PCR was performed on cDNA from a panel of human leukemia cell
in all subtypes of leukemia cell lines, as compared with normal hematopoietic
Fig. 2. Increased ANKHD1 mRNA expression in primary leukemia cells. Real-time quantitative RT-PCR was performed on cDNA from fresh leukemia cell samples
from patients at diagnosis or from normal hematopoietic cells. Horizontal lines represent medians. ANKHD1mRNA expression was significantly higher in all primary
acute leukemias samples (P=0.002), acute myeloid leukemias (AML) (P=0.004) and acute lymphoblastic leukemias (ALL) (P=0.005) when compared with normal
hematopoietic cells.
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Reverse transcription, primer sequences and real-time quantitative RT-
PCR was performed as previously described [17]. Briefly, real-time detectionFig. 3. Analysis of the ANKHD1 protein expression. Western blot analysis of peri
human cancer cell lines (A) and various human normal tissues (B) for the expres
antibodies against ANKHD1 (270 kDa) or actin (42 kDa), as a control for equ
System.of amplification was performed in an ABI 5700 Sequence Detector System
(Applied Biosystems) using SybrGreen PCR Master Mix (Applied Biosys-
tems). Four replicas were run on the same plate for each sample. β-Actin
expression was used as an endogenous control and a pool of 3 normal bonepheral blood mononuclear cells (PBMNC) from 4 healthy donors (N1 to N4),
sion of the ANKHD1 protein. Total tissue or cell extracts were blotted with
al sample loading, and developed with the ECL Western Blotting Analysis
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ANKHD1 gene expression was calculated using the 2−ΔΔCT [18].
2.7. Statistical analysis
The relative level of ANKHD1 mRNA expression was compared between
normal hematopoietic cells, all primary acute leukemia samples, primary AML
samples and primary ALL samples using a Mann–Whitney U test. A P value of
≤0.05 was considered to indicate statistical significance.
3. Results
3.1. ANKHD1 mRNA is highly expressed in leukemia cells
Real-time RT-PCR demonstrated increased levels of
ANKHD1 mRNA in all leukemia cell lines studied; KG-1,
HEL, K562, NB4, HL-60 Jurkat, MOLT4, Raji, Daudi and
Namalwa (up to 10-fold increase), as compared with normal
bone marrow cells (Fig. 1).
ANKHD1 mRNA expression was significantly higher in
primary acute leukemia samples when compared with normal
hematopoietic cells (medians: 2.21 versus 1.05, P=0.002), and in
ALL (medians: 2.53 versus 1.05, P=0.005) and AML (medians:
1.97 versus 1.05, P=0.004) when compared with normal
hematopoietic cells. No significant difference in ANKHD1Fig. 4. Laser confocal analysis. K562 and Jurkat cells (A) were fixed and permeab
antibody (green fluorescence). Phalloidin was used to visualize the actin (red fluores
and methods. Positive immunoreactivity was visualized by laser confocal scanning
indicates regions of red/green overlap. Normal peripheral blood mononuclear cells (PB
conjugated anti-ANKHD1 antibody (green fluorescence). Propidium iodide (PI) was
visualized by laser confocal scanning (Zeiss LM510).mRNA expression was observed in the comparison of AML
versus ALL (Fig. 2). Among the AML samples, ANKHD1
mRNA expression tended to be higher in the subtypes AML M1
and AML M2; however, there was no statistical significance
among the subtypes ofAML; neither among the subtypes ofALL.
3.2. ANKHD1 protein is highly expressed in leukemia cells
Immunoblot analysis detected a very low expression of
ANKHD1 in PBMNC of normal donors. Conversely, a high
expression of the protein was detected in the human leukemia
cell lines (Fig. 3A); the expression of ANKHD1 was character-
ized with 2 bands of approximately 270-kDa in the immunoblot
of leukemia cells, and the expression of ANKHD1 in LNCaP
was used as a positive control, as previously described [6].
A broad expression of ANKHD1 was observed in all normal
human tissues here studied, with a high expression in stomach,
small intestine and lymph node and a low expression in liver,
spleen, lung, kidney and skeletal muscle (Fig. 3B). Only 1 band
of approximately 270 kDa, corresponding to ANKHD1, was
detected in normal human tissues.
Immunoblotting analysis of leukemia cell lines with anti-
phosphotyrosine antibody revealed that ANKHD1 was not
phosphorylated at tyrosine (data not shown).ilized and ANKHD1 was visualized by Alexa 488-conjugated anti-ANKHD1
cence) and DAPI to mark the nuclei (blue fluorescence), as detailed in Materials
(Zeiss LM510). In the red, green and blue overlay (merge) the yellow signal
MC) (B) were fixed, permeabilized and ANKHD1 was visualized by Alexa 488
used to visualize the nuclei (red fluorescence). Positive immunoreactivity was
Fig. 5. Subcellular localization of ANKHD1 in the Jurkat cell line. Jurkat cells
were lysed in hypotonic buffer and lysates were used to prepare total cellular
protein extract (TE), cytosolic and membrane (C+M) and nucleus (N) fractions.
An aliquot of each fraction (100 μg total proteins) was subjected to immunoblot
analysis for ANKHD1. Anti-actin and anti-histone were used as the controls of
subcellular fractions.
Fig. 6. ANKHD1 is a substrate of SHP2 protein. Lysates from K562 or LNCaP
cells containing equal amounts of protein were immunoprecipitated (IP) in
duplicate with anti-SHP2 antibodies (upper panel), anti-ANKHD1 antibodies
(middle panel) or normal rabbit IgG (bottom panel) and immunoblotted (IB)
with anti-ANKD1 antibodies or anti-SHP2 antibodies. K562 and LNCaP total
cell extract (TE) were used as a positive control for the immunoblotting with
anti-ANKHD1 or anti-SHP2 (bottom panel). Western blots were developed with
the ECLWestern Blotting Analysis System.
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Laser confocal analysis of K562 and Jurkat cell lines (Fig.
4A) and PBMNC (Fig. 4B) showed that ANKHD1 is located in
the cytoplasm of leukemia and normal hematopoietic cells. This
cytoplasmatic localization of ANKHD1 was further examined
by immunoblotting performed with anti-ANKHD1 antibody
and tissue fractions of Jurkat cell line (Fig. 5).
3.4. Association of ANKHD1 and SHP2 in cancer cell lines
Immunoprecipitation analysis was carried out using anti-
ANKHD1 antibody. ANKHD1 was co-immunoprecipitated
with SHP2 in protein extracts of K562 and LNCaP cell lines
(Fig. 6, upper panels). To double-check this interaction, we
performed the reverse assay; SHP2 was co-immunoprecipitated
with ANKHD1 in the protein extracts of K562 and LNCaP cell
lines (Fig. 6, middle panels), indicating that ANKHD1 protein
associates with SHP2 in vivo. As a negative control for all
assays, cell lysates were immunoprecipitated with rabbit
polyclonal IgG and immunoblotted with anti-SHP2 or anti-
ANKHD1, no band was observed; total extracts were used as a
positive control for the immunoblot (Fig. 6, bottom panels).
ANKHD1 was not found to be associated with SHP2 in
KG1, HL60, Daudi and Jurkat cell lines, even though all
leukemia cell line studies presented a high level of SHP2 protein
expression (Fig. 7).
4. Discussion
We, herein, report increased levels of ANKHD1 mRNA
and protein expression in leukemia cell lines, as compared
with normal hematopoietic cells, and a higher expression of
ANKHD1 mRNA in primary acute leukemia samples, as
compared with normal hematopoietic cells. Furthermore,
Western blot analysis demonstrated a broad expression of
ANKHD1 in normal human tissues. ANKHD1 is an
orthologous protein of Drosophila MASK, suggesting that
ANKHD1 belongs to a protein family conserved through
evolution. In Drosophila, Mask was identified through a
genetic screen to identify potential targets of CSW, theDrosophila homologue of SHP2 [5]. In this study, the
association of ANKHD1 with SHP2 was identified by
immunoprecipitation in K562 and LNCaP cell lines. We
also demonstrated that ANKHD1 is located in the cytoplasm
of the cells, similar to the subcellular localization of SHP2 in
leukemia cells [15], indicating that these proteins share
subcellular compartments. Moreover, the expression pattern
of ANKHD1 was found to be similar to that of SHP2, which
is overexpressed in acute leukemia cell lines and primary
leukemia cells [15].
In Drosophila, Mask was characterized as a novel protein
involved in RTKs [5]. Our findings that ANKHD1 is not
phosphorylated in tyrosine suggest that ANKHD1 may function
as an adaptor protein, since SHP2 binds directly to some RTKs
or to one or more scaffolding adapter proteins [8,19]. Protein–
protein interactions are crucial for all biological processes. The
generation of accurate cellular protein interaction networks is an
ongoing process, in which the data produced by the study of
new proteins contributes in a complementary manner.
SHP2 is a widely expressed protein–tyrosine phosphatase
that seems to play a positive role in the activation ofMAP kinase
in response to growth factors [20,21]. Rongzhen Xu and
colleagues [15] demonstrated that overexpression and constitu-
tive activation of SHP2 protein is a common phenotype in
various types of human leukemia and are closely associated with
Fig. 7. High SHP2 protein expression in human cancer cell lines. Western blot analysis of human cancer cell lines for the expression of the SHP2 protein. Cell extracts
were blotted with antibodies against SHP2 (70 kDa) or actin (42 kDa), as a control for equal sample loading, and developed with the ECLWestern Blotting Analysis
System.
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expression of SHP2 might not be sufficient for the development
of leukemia, and other factors may be required for leukemogen-
esis [15]. In this context, the finding that ANKHD1 is associated
with SHP2 in K562 and LNCaP cells, and that ANKHD1mRNA
is overexpressed in primary leukemia cells compared to normal
hematopoietic cells suggests that ANKHD1 may be an adaptor
protein and that its association with SHP2 may be required for
leukemogenesis and the development of other cancers. How-
ever, the finding that ANKHD1 is not associated with SHP2 in
KG1, HL60, Daudi and Jurkat cell lines, even though all
leukemia cell line studies presented a high level of SHP2 protein
expression, gives rise to the hypothesis that the association
between ANKHD1 and SHP2 may be tissue specific and may
play a different role in different cells. Another possible
explanation for the different pattern of association may be the
presence of variants of ANKHD1 and/or SHP2 within these cell
lines. Besides, PTPN11 mutations can also lead to SHP2
variants with altered susceptibility to activation and modified
substrate selectively [22].
The previous findings that ANKHD1 interacts with
GRINL1A [23], which has been recently identified as a
cancer/testis antigen expressed in bone marrow and peripheral
blood from AML patients, but not in normal donor samples
[24], as well as the high expression of ANKHD1 in acute
leukemia, described in our study, corroborate our hypothesis
that ANKHD1 protein may be involved in leukemogenesis. The
identification of new disease-specific targets for AML immu-
notherapy expands treatment options and increases our chances
of successfully treating this heterogeneous disease and lowering
the unacceptably high mortality rate.
Ankyrin repeat proteins carry out a wide variety of biological
activities and have been detected in organisms ranging from
viruses to humans [4]. Two new variants of ANKHD1, Vpr-
binding ankyrin repeat proteins (VAPR-L and VAPR-S), may
possess an antiapoptotic effect and protect cells during normal
cell proliferation in HeLa and NT2 cells [25]. Like other ankyrin
repeat proteins, ANKHD1, through its association with SHP2,
may have a role in regulating cell proliferation; however, the
exact role of ANKHD1 in acute leukemias is not yet fully
understood and requires further studies.
ANKHD1 has a ubiquitous expression in normal human
tissues and has a varied higher expression in acute leukemias.The presence of multiple ankyrin repeats suggests a role for
ANKHD1 as a scaffolding protein, bringing together many
signaling molecules. Our findings are the first to describe the
expression of ANKHD1 in different human tissues and to
characterize the association of ANKHD1 with SHP2. The
identification of proteins that interact with ANKHD1 and that
might direct ANKHD1 to various signal transduction path-
ways is essential to clarify the role of ANKHD1 in the
signaling pathways in general. The higher expression of
ANKHD1 in acute leukemia may be associated with the
abnormal phenotype of the leukemia cell and may be a
molecular target for a rational therapy for leukemia in the
near future.
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